Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lyra Therapeutics Inc (NQ: LYRA )

5.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.250
Bid (Size) 4.470 (2)
Ask (Size) 6.990 (2)
Prev. Close 5.250
Today's Range 5.250 - 5.250
52wk Range 2.360 - 6.790
Shares Outstanding 31,836,815
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024
LYRA stock results show that Lyra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+0.96%
+0.96%
1 Month
-16.00%
-16.00%
3 Month
+15.38%
+15.38%
6 Month
+77.97%
+77.97%
1 Year
+92.31%
+92.31%

More News

Read More
What 4 Analyst Ratings Have To Say About Lyra Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
Via Benzinga
Lyra Therapeutics: Q1 Earnings Insights
Via Benzinga
Lyra Therapeutics's Return On Capital Employed Insights
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
Lyra Therapeutics: Q2 Earnings Insights
Via Benzinga
Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor
Via Benzinga
Recap: Lyra Therapeutics Q1 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Lyra Therapeutics's Return On Capital Employed Insights
Via Benzinga
7 Stocks to Watch for Major Insider Trading Clues
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
90 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.